Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks

As major U.S. stock indexes experience slight declines, investors are keenly analyzing earnings reports and economic indicators to gauge the market's direction. In this context, penny stocks continue to capture attention for their potential value, despite being a term that may seem outdated. These smaller or newer companies can offer compelling investment opportunities when they exhibit strong financial foundations, and we will explore several such stocks that stand out in the current market landscape.

Advertisement

Top 10 Penny Stocks In The United States

NameShare PriceMarket CapFinancial Health Rating
BAB (OTCPK:BABB)$0.7988$5.8M★★★★★★
LexinFintech Holdings (NasdaqGS:LX)$3.15$485.02M★★★★★★
Flexible Solutions International (NYSEAM:FSI)$3.47$45.02M★★★★★★
RLX Technology (NYSE:RLX)$1.62$2.1B★★★★★★
ARC Document Solutions (NYSE:ARC)$3.42$147.91M★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)$3.77$114.05M★★★★★★
Permianville Royalty Trust (NYSE:PVL)$1.57$52.63M★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)$4.50$69.71M★★★★★★
PHX Minerals (NYSE:PHX)$3.63$137.99M★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)$1.09$96.23M★★★★★☆

Click here to see the full list of 752 stocks from our US Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

Incannex Healthcare (NasdaqGM:IXHL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Incannex Healthcare Inc. is a clinical stage pharmaceutical development company focused on medicinal cannabinoid and psychedelic products, with a market cap of $41.64 million.

Operations: The company's revenue is derived from its segment focused on psychedelic medicine and therapies for the treatment of mental health disorders, generating $0.012 million.

Market Cap: $41.64M

Incannex Healthcare Inc., a clinical-stage pharmaceutical company, remains pre-revenue with sales of just US$0.012 million and a net loss of US$18.46 million for the year ending June 2024. The company's strategic focus on psychedelic medicine is underscored by recent FDA approval for its Phase 2 clinical trial investigating psilocybin for anxiety disorders. Additionally, Incannex secured A$6.9 million in debt financing aligned with Australia's R&D Tax Incentive program, providing non-dilutive funding essential for ongoing research without impacting shareholder equity. Despite high volatility and an inexperienced management team, these developments highlight potential growth avenues in innovative therapies.

NasdaqGM:IXHL Financial Position Analysis as at Oct 2024
NasdaqGM:IXHL Financial Position Analysis as at Oct 2024

Performant Financial (NasdaqGS:PFMT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Performant Financial Corporation offers technology-enabled audit, recovery, and analytics services in the United States and has a market cap of approximately $294.86 million.

Operations: The company's revenue is derived from its Business Services segment, totaling $119.23 million.

Market Cap: $294.86M

Performant Financial Corporation, with a market cap of approximately US$294.86 million, has shown revenue growth in its Business Services segment, reporting US$29.36 million for Q2 2024. Despite being unprofitable, the company has reduced losses over five years and maintains a strong cash position exceeding its total debt. Revenue is forecasted to grow by 13.01% annually, though profitability remains elusive in the near term. Recent shelf registration filings totaling US$143.56 million suggest potential capital raising activities to support operations or expansion plans, while analyst consensus indicates significant upside potential in stock price appreciation despite current undervaluation concerns.

NasdaqGS:PFMT Debt to Equity History and Analysis as at Oct 2024
NasdaqGS:PFMT Debt to Equity History and Analysis as at Oct 2024

FREYR Battery (NYSE:FREY)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: FREYR Battery, Inc. offers battery solutions across the United States, Norway, and internationally with a market cap of approximately $147.51 million.

Operations: FREYR Battery, Inc. does not have any reported revenue segments at this time.

Market Cap: $147.51M

FREYR Battery, Inc., with a market cap of approximately US$147.51 million, is a pre-revenue company in the battery solutions sector. The firm has experienced significant volatility in its share price and remains unprofitable with increasing losses over the past five years. Despite this, it maintains a strong cash position, with short-term assets of US$234.4 million exceeding both short-term and long-term liabilities. Recent executive changes include appointing Michael Brose as COO to bolster operations amid strategic shifts following re-domiciliation to the U.S., while shelf registration filings indicate potential capital raising activities for future growth initiatives.

NYSE:FREY Financial Position Analysis as at Oct 2024
NYSE:FREY Financial Position Analysis as at Oct 2024

Make It Happen

  • Get an in-depth perspective on all 752 US Penny Stocks by using our screener here.
  • Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
  • Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqCM:IXHL

Incannex Healthcare

A clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia.

Flawless balance sheet with slight risk.

Advertisement

Weekly Picks

WE
WealthAP
PYPL logo
WealthAP on PayPal Holdings ·

The "Sleeping Giant" Stumbles, Then Wakes Up

Fair Value:US$8229.7% undervalued
75 users have followed this narrative
6 users have commented on this narrative
34 users have liked this narrative
WO
BMBL logo
woodworthfund on Bumble ·

Swiped Left by Wall Street: The BMBL Rebound Trade

Fair Value:US$960.1% undervalued
23 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
DUOL logo
WealthAP on Duolingo ·

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For

Fair Value:US$268.6441.8% undervalued
45 users have followed this narrative
5 users have commented on this narrative
9 users have liked this narrative
AN
andre_santos
RACE logo
andre_santos on Ferrari ·

Ferrari's Intrinsic and Historical Valuation

Fair Value:€243.5625.8% overvalued
9 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative

Updated Narratives

YI
BKNG logo
yiannisz on Booking Holdings ·

Booking Holdings: Why Ground-Level Travel Trends Still Favor the Platform Giants

Fair Value:US$5.47k5.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5369.3% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
andre_santos
ADBE logo
andre_santos on Adobe ·

Adobe - A Fundamental and Historical Valuation

Fair Value:US$356.9814.7% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

WE
WealthAP
PYPL logo
WealthAP on PayPal Holdings ·

The "Sleeping Giant" Stumbles, Then Wakes Up

Fair Value:US$8229.7% undervalued
75 users have followed this narrative
6 users have commented on this narrative
34 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
72 users have followed this narrative
15 users have commented on this narrative
23 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25464.9% overvalued
76 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
Advertisement